News | December 10, 2023
Briefs: GlaxoSmithKline Pharmaceuticals and Dr. Reddy's Laboratories
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
The company has received Form 483 with three observations
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Emphasizes the need for a collective effort on bolstering resilience across economies, societies, healthcare systems, education systems and infrastructure
Subscribe To Our Newsletter & Stay Updated
